INDUSTRY WORKSHOPS 

Tuesday October 6, 2009, 0700-0800 includes breakfast Sponsored by Roche Topic: The How, Why and When of Oral Based Diagnostics    Wednesday October 7, 2009, 1600-1730 Sponsored by Siemens Topic: Current Strategies and New Insights into Monitoring Immunosuppressive Drugs    Wednesday October 7, 2009, 1600-1730 Sponsored by ChromSystems Topic: Novel Diagnostic Assays For Immunosuppressants , Anti-Psychotic Drugs And 25-Oh-Vitamin D3/D2 Analysis By Tandem Mass Spectrometry    Wednesday October 7, 2009, 1600-1730 Sponsored by Waters Topic: LC/MS/MS      TUESDAY OCTOBER 6, 2009, 0700-0800   Industry Workshop IW301 The How, Why and When of Oral Based Diagnostics Sponsored by Roche    Speaker: Sam Niedbala PhD Workshop description: Oral fluid offers a wide range of advantages as a matrix for drug testing and is routinely used in workplace, criminal justice and insurance risk settings. While hospitals and clinical laboratories have continued relying primarily on urine and blood for their drug testing samples, these labs are also beginning to look at oral fluid not only for drug testing but also for cancer and protein markers, infectious disease, genetic testing and as well as other applications. Objectives: This presentation will offer participants an overview of the physiology of oral fluid, collection processes, and testing methodologies – both current and in development - including development of applications for LC-MS/MS.     WEDNESDAY OCTOBER 7, 2009, 1600-1730 | 3 concurrent workshops   Industry Workshop IW401 Novel Diagnostic Assays For Immunosuppressants , Anti-Psychotic Drugs And 25-Oh-Vitamin D3/D2 Analysis By Tandem Mass Spectrometry Sponsored by ChromSystems    Chair: Dr. Frank Kühlwein, Chromsystems GmbH ABSTRACT: Tandem Mass Spectrometry is progressively gaining more access into routine diagnostic laboratories, shedding its image as a complicated and laborious technique. This is a result of more user friendly instrumentation and the rise of ready-to use assays. The development of know-how enabling laboratories to easily identify and quantify diagnostic markers paves the way for general recognition of LCMS/MS as a tool for routine diagnostic analyses. Fast sample preparation, easy instrument calibration and reliable quality control are main features of commercially available reagent kits; qualities unconditionally required by high sample throughput. Novel reagent kits facilitate routine method development and ensure that analysts overcome classic drawbacks of self-made methods, such as ion suppression and significant inter-assay variation. New software ensures analysis-specific tuning and optimised use of the tandem mass spectrometer and customized evaluation of the produced data. Down times of the instrumentation are essentially eliminated. Presenting the principals and features of the newly available assays designed for the MS/MS analysis of immunosuppressant drugs, psychoactive drugs and vitamins D3 and D2, the author takes emphasis in describing also the benefits over traditional methods. Presentation 1: Latest Developments in Clinical Diagnostics with Tandem Mass Spectrometry – Novel Diagnostic Kits & Quality Controls and their Value for Clinical Laboratories Dr. Frank Kühlwein, Chromsystems GmbH, Munich, Germany Talk time: 25 min. Presentation 2: Recently launched Tandem-MS Kits for, Immunosuppressant and Anti-psychotic Drugs and 25-OH Vitamin D3/D2 Oliver Wenzel, Chromsystems GmbH, Munich, Germany Talk time: 20 min. Presentation 3: iMethods and the new Cliquid Software – New Product and Software launches and their advantage for Clinical Research Laboratories Lisa Sapp, Applied Biosystems, United States Talk time: 15 min.       Industry Workshop IW402 Current strategies and new insights into monitoring immunosuppressive drugs Sponsored by Siemens     Chair: Dr. Claus Pruemper, Siemens Healthcare Diagnostics 4:00 - 4:10 pm Welcome & Introduction 4:10 - 4:50 pm New insights into monitoring Immunosuppressive Drugs Steven J. Soldin, PhD, FACB, Director of the Bioanalytical Mass Spectrometry Laboratory Georgetown University and the Clinical Endocrinology Laboratory at NMS in Pennsylvania, US. 4:50 - 5:20 pm Current strategies to monitor the functional activity of Mycophenolate Mofetil (MMF) therapy in transplant recipients Dr. M. Regazzi, Head of the Clinical Pharmacokinetic Laboratory, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy 5:20 - 5:30 pm Summary, Q&A Objectives: At the end of Dr. Soldin's presentation, the participants should be able to: - Describe the immunosuppressive drugs that require monitoring - Understand the toxicities associated with today's immunosuppressive drugs - Understand the current methodologies used to measure Immunosuppressive drugs At the end of Dr. Regazzi's presentation, the participants should be able to: - Understand that MPA concentrations have a predictive value for the risk of both acute rejection and serious hematologic toxicity - Describe the challenges in establishing therapeutic ranges - Understand critical steps toward customizing MPA treatment to the individual patient.   Industry Workshop IW403 Sponsored by Waters    This workshop is the perfect opportunity to learn from industry experts how LC/MS/MS can solve challenging clinical chemistry problems. The following speakers will present at the workshop: Paul J Taylor, BSc Senior Scientist, Department of Medicine, University of Queensland, Department of Clinical Pharmacology Princess Alexandra Hospital, Brisbane, Queensland, Australia Senior Scientist, Department of Clinical Pharmacology Princess Alexandra Hospital Brisbane, Australia Prof P Wallemacq, PhD, EurClinChem Laboratory of Toxicology and Clinical Chemistry University Hospital St Luc Brussels, Belguim Prof. Michel Lhermitte Scientific co-ordinator, Faculté de Pharmacie University Hospital Lille, France

 

IATDMCT 2009 Congress Secretariat

Email: congress@eventsmgt.com

4 Cataraqui Street, Suite 310

Kingston, ON  K7K 1Z7

Tel: +1-613-531-8166  /  Fax: +1-613-531-0626